MHC Class-I Loss and Cancer Immune Escape (Paperback)

Introduction

I.-     MHC/HLA class I loss in Primary Tumours

 1-1.            MHC-I heterogeneity in primary mouse sarcomas

 1-2.            HLA-I Heterogeneity in primary human tumours

       1.3       Altered HLA-I tumour phenotypes

1-4        Molecular mechanisms underlying HLA-I altered expression

        1-5       Reversible “soft” and irreversible “hard” molecular HLA-I lesions 

1-6        T-cell immune selection of HLA-I negative tumour variants

1-7       HLA-I expression in different tumour tissues: melanoma, colorectal,

                     cervix, bladder, breast, gastric, head and neck, lung, pancreas, prostate

                     and thyroid carcinomas

1-8        An exception to the rule: HLA-I expression in renal cell carcinoma

1-9        An exception to the rule: T cell infiltration in MSI-H, HLA-I

II.-    MHC/HLA class I loss in metastases

         2-1        H-2 class I expression in spontaneous metastases in mice

         2-2        HLA class I expression in human metastases

         2-3        HLA-I expression in progressing and regressing metastases after

                       immunotherapy

III.-   Recovery of HLA-I antigen expression in cancer cells: a

         challenge for the future

IV.-    HLA- class II expression in human tumors  

Concluding remarks